<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2134">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901679</url>
  </required_header>
  <id_info>
    <org_study_id>PHO-0807</org_study_id>
    <nct_id>NCT01901679</nct_id>
  </id_info>
  <brief_title>Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women</brief_title>
  <official_title>A Pilot Study: Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study plans to find out whether Celebrex may be potentially useful to decrease&#xD;
      inflammation in fat tissues and thereby lower the production of substances such as estrogens&#xD;
      that may increase the risk of developing breast cancer and lead to a poor outcome of the&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to examine how effective the celebrex may be in reducing inflammation,&#xD;
      crown-like structures in fat tissue, the enzyme aromatase, PGE-M in the urine and estrogen in&#xD;
      blood and urine. Volunteer subjects will be expected to stay in the hospital for about 2&#xD;
      weeks taking Celebrex for approximately 10 days while eating a diet similar to what they&#xD;
      consumed before coming into the hospital for the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine Whether Oral Administration of Celebrex to Obese Women Will Reduce the PGE-M in Urine</measure>
    <time_frame>10 days</time_frame>
    <description>Study endpoint is a reduction in PGE-M in urine after treatment with celebrex</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Celebrex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days treatment with Celebrex to evaluate reduction of PGE-M in urine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex</intervention_name>
    <description>200 mg PO BID</description>
    <arm_group_label>Celebrex</arm_group_label>
    <other_name>Celecoxib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal woman defined as: 24 consecutive months without a menstrual period and&#xD;
             currently not taking any medication known to induce amenorrhea.&#xD;
&#xD;
          -  Serum estradiol &lt; 20 pg/mL&#xD;
&#xD;
          -  Body Mass Index of 35-50&#xD;
&#xD;
          -  Stable weight defined as (+/- 5 %) of body weight for at least three months&#xD;
&#xD;
          -  40-70 years of age&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to celecoxib or sulfonamides&#xD;
&#xD;
          -  Known peptic ulcer disease&#xD;
&#xD;
          -  Hypertension BP &gt; 150/90 (on 2 occasions after resting)&#xD;
&#xD;
          -  Fasting blood glucose &gt; 165 mg/dL&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Screening creatinine &gt; 2X upper limit of normal&#xD;
&#xD;
          -  Screening LFT results &gt; 2x upper limit of normal&#xD;
&#xD;
          -  Smokers (or stopped &lt; 3 months ago)&#xD;
&#xD;
          -  Framingham risk score &gt; 15&#xD;
&#xD;
          -  Evidence of active coronary disease by history and/or EKG&#xD;
&#xD;
          -  Subjects who consume 25 grams of soy protein/day or more than 45 mg of&#xD;
             isoflavones/day, for subjects who consume this amount of soy, they may stop for 14&#xD;
             days prior to admission&#xD;
&#xD;
          -  Currently taking NSAIDS, aspirin, (if &gt; once a week, stopped &lt;30 days ago).&#xD;
&#xD;
          -  Consuming &gt; 3 servings of fish or seafood/week&#xD;
&#xD;
          -  Currently taking fish oil, omega-3 supplements or other herbal supplements that exceed&#xD;
             GRAS (Generally Recognized as Safe) levels, (if currently taking fish oil/omega-3&#xD;
             supplements, there must be a 30 day washout period)&#xD;
&#xD;
          -  Current use of anti-coagulants&#xD;
&#xD;
          -  Currently taking any weight control medication&#xD;
&#xD;
          -  Currently taking thioridazine&#xD;
&#xD;
          -  Currently taking lithium&#xD;
&#xD;
          -  Currently taking any estrogen/progesterone hormones including vaginal cream, e-string,&#xD;
             or vaginal tablets&#xD;
&#xD;
          -  Currently taking any medication that can alter fat stores as determined by the&#xD;
             principal investigator&#xD;
&#xD;
          -  History of Inflammatory Bowel Disease or other chronic inflammatory disorders&#xD;
&#xD;
          -  History of any malignancy other than non-melanoma skin cancer in the past 5 years&#xD;
&#xD;
          -  History of any bleeding disorder&#xD;
&#xD;
          -  History of cardiovascular disease&#xD;
&#xD;
          -  Diagnosis of asthma&#xD;
&#xD;
          -  Any medical, psychological or social condition that, in the opinion of the&#xD;
             Investigator, would jeopardize the health or well-being of the participant during any&#xD;
             study procedures or the integrity of the data.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Holt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <results_first_submitted>November 13, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2021</results_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Post-menopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01901679/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted during 2 outpatient visits at Rockefeller University Hospital outpatient clinic. Recruitment of subjects began on 6/10/13 and was completed on 6/30/14.</recruitment_details>
      <pre_assignment_details>All participants were screened for their usual dietary intake and instructed to continue to follow their usual diet during weeks prior to hospital admission and thoughout the entire study. .&#xD;
First group underwent 3 day run-in period inpatient, the second group underwent 14 day run-in period prior to starting Celecoxib 200mg po BID X 10 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1st Group: 3 Day run-in Period</title>
          <description>After 3 day run-in period, participants underwent baseline testing then started 10 days of Celecoxib 200mg po BID. Follow-up blood and stool collection was performed as outpatients 7-10 days after discharge.</description>
        </group>
        <group group_id="P2">
          <title>2nd Group: 14 Day run-in Period</title>
          <description>After 14 day run-in period, participants underwent baseline testing then started 10 days of Celecoxib 200mg po BID. Follow-up blood and stool collection was performed as outpatients 7-10 days after discharge.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3 Day run-in Period</title>
          <description>After 3 day run-in period, participants underwent baseline testing then started 10 days of Celecoxib 200mg po BID. Follow-up blood and stool collection was performed as outpatients 7-10 days after discharge.</description>
        </group>
        <group group_id="B2">
          <title>14 Day run-in Period</title>
          <description>After 14 day run-in period, participants underwent baseline testing then started 10 days of Celecoxib 200mg po BID. Follow-up blood and stool collection was performed as outpatients 7-10 days after discharge.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="56" upper_limit="68"/>
                    <measurement group_id="B2" value="56" lower_limit="53" upper_limit="60"/>
                    <measurement group_id="B3" value="59" lower_limit="53" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" lower_limit="38.2" upper_limit="43.1"/>
                    <measurement group_id="B2" value="39.7" lower_limit="36.7" upper_limit="45.1"/>
                    <measurement group_id="B3" value="40.0" lower_limit="36.7" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine Whether Oral Administration of Celebrex to Obese Women Will Reduce the PGE-M in Urine</title>
        <description>Study endpoint is a reduction in PGE-M in urine after treatment with celebrex</description>
        <time_frame>10 days</time_frame>
        <population>These samples were collected but not analyzed due to technical reasons. Investigator has retired and access to results was not available for this outcome. Best efforts were made to obtain the data; however, they were unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>1st Group: 3 Day run-in Period</title>
            <description>After 3 day run-in period, participants underwent baseline testing then started 10 days of Celecoxib 200mg po BID. Follow-up blood and stool collection was performed as outpatients 7-10 days after discharge.</description>
          </group>
          <group group_id="O2">
            <title>2nd Group: 14 Day run-in Period</title>
            <description>After 14 day run-in period, participants underwent baseline testing then started 10 days of Celecoxib 200mg po BID. Follow-up blood and stool collection was performed as outpatients 7-10 days after discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Whether Oral Administration of Celebrex to Obese Women Will Reduce the PGE-M in Urine</title>
          <description>Study endpoint is a reduction in PGE-M in urine after treatment with celebrex</description>
          <population>These samples were collected but not analyzed due to technical reasons. Investigator has retired and access to results was not available for this outcome. Best efforts were made to obtain the data; however, they were unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collected during inpatient phase of study, an average of 14 days for 3 day run-in period or 24 days for 14 day run-in period</time_frame>
      <desc>AE's were reported when discovered. Reports were from investigator assessment, nursing assessment and patient complaints. All AE's were documented and submitted to the IRBand PI as per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>1st Group: 3 Day run-in Period</title>
          <description>After 3 day run-in period, participants underwent baseline testing then started 10 days of Celecoxib 200mg po BID. Follow-up blood and stool collection was performed as outpatients 7-10 days after discharge.</description>
        </group>
        <group group_id="E2">
          <title>2nd Group: 14 Day run-in Period</title>
          <description>After 14 day run-in period, participants underwent baseline testing then started 10 days of Celecoxib 200mg po BID. Follow-up blood and stool collection was performed as outpatients 7-10 days after discharge.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>hemorrhage</sub_title>
                <description>During abdominal fat biopsy procedure, there was moderate bleeding from the site. Procedure was stopped, and the bleeding ceased. Subject was stable and recovered promptly, but was monitored for an additional day for safety.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atypical chest pain</sub_title>
                <description>Subject complained of chest pain after burning her skin with hot tea.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bloating and constipation</sub_title>
                <description>Subject complained of bloating and constipation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>bruise at biopsy site</sub_title>
                <description>Due to the pinching of abdominal fat during the fat biopsy, a resultant bruise medial to the incision is common and expected. It resolved within 3-4 days and well tolerated. The risk is addressed in the informed consent.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>elevated serum cholesterol</sub_title>
                <description>Subjet had history of hypercholesteremia. She stopped taking statin medication prescribed by PMD. Cholesterol level increased. PMD was informed and given test results.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>elevated ALT</sub_title>
                <description>After 10 days on celecoxib, subject had mild elevation in ALT</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>sore throat and dry cough</sub_title>
                <description>Subject complained of sore throat and dry cough after a group gathering. Afebrile.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>burn</sub_title>
                <description>Participant spilled hot tea on her chest wall resulting in 1st degree scald burn of her upper chest.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter R Holt</name_or_title>
      <organization>The Rockefeller University</organization>
      <phone>212-327-7706</phone>
      <email>holtp@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

